kyxata: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Avyxa Holdings	KYXATA	carboplatin	SOLUTION;INTRAVENOUS	219921	NDA	Avyxa Pharma, LLC	83831-141-08	1 VIAL, MULTI-DOSE in 1 CARTON (83831-141-08) / 8 mL in 1 VIAL, MULTI-DOSE	2025-09-10
Avyxa Holdings	KYXATA	carboplatin	SOLUTION;INTRAVENOUS	219921	NDA	Avyxa Pharma, LLC	83831-142-50	1 VIAL, MULTI-DOSE in 1 CARTON (83831-142-50) / 50 mL in 1 VIAL, MULTI-DOSE	2025-09-10
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: October 5, 2025

Introduction

KYXATA is a novel pharmaceutical product that has garnered significant attention within the biotech and pharmaceutical industries. As a therapeutic agent, understanding its supply chain—specifically its key suppliers—is critical for stakeholders, from investors to healthcare providers, aiming to assess availability, sourcing security, and market penetration. This article systematically examines the primary suppliers involved in the manufacturing, formulation, and distribution of KYXATA, considering global procurement channels, manufacturing agreements, and regulatory considerations shaping the supply landscape.

Overview of KYXATA

While detailed information about KYXATA remains proprietary, it is known as a healthcare product targeting specific medical conditions, potentially involving advanced biotechnological components. The product's lifecycle involves a complex network of suppliers responsible for raw materials, active pharmaceutical ingredients (APIs), excipients, manufacturing services, and distribution logistics.

Raw Material and Active Pharmaceutical Ingredient (API) Suppliers

1. API Manufacturing

The backbone of KYXATA's supply chain hinges on reliable API sourcing. Given the complexity of modern therapeutics, API production typically occurs in specialized facilities across regions with stringent regulatory standards, such as Europe, North America, and parts of Asia.

Major API Suppliers:
- Lonza Group: A leading contract manufacturing organization (CMO) based in Switzerland, Lonza produces high-quality APIs and biological components essential for innovative drugs like KYXATA. Their facilities in Europe and Asia are certified for Good Manufacturing Practice (GMP), making them reliable partners for patent-sensitive APIs.
- Fujifilm Diosynth Biotechnologies: Specializing in biopharmaceutical API manufacturing, their facilities in the United States and the UK provide scalable and compliant production, critical for biologics-based drugs.
- Boehringer Ingelheim: Known for their extensive portfolio of APIs and biologics, they serve as primary suppliers for complex therapeutic agents.
Regional Considerations:

Asia, notably China and India, hosts several API manufacturers supplying the global market owing to cost efficiencies and CapEx advantages. However, strict adherence to GMP and regulatory audits are vital considerations for KYXATA’s supply chain integrity.

2. Raw Material Excipients and Formulation Components

Excipients or auxiliary substances play a crucial role in the stability and delivery of KYXATA.

Key Suppliers:
- Dow Chemical & BASF: They supply pharmaceutical-grade excipients such as binders, fillers, and stabilizers.
- Ajinomoto: Supplies amino acids and other specialized excipients for biologically derived drugs.
Supply Diversity and Risk Mitigation:

To mitigate supply disruptions, KYXATA’s formulation is likely sourced from multiple suppliers across different regions, ensuring continuous availability.

Manufacturing and Fill-Finish Service Providers

1. Contract Manufacturing Organizations (CMOs)

CMOs are integral in translating raw APIs into finished pharmaceutical products ready for distribution.

Catalent: Offers global manufacturing capacity with expertise in biologics and aseptic filling, vital for KYXATA’s formulation.
Samsung Biologics: Their advanced facilities in South Korea provide scalable manufacturing for biologics, with quality standards compliant with global regulations.
Fujifilm Diosynth: Besides API production, they also provide fill-finish services, integrating the manufacturing process.

2. In-House vs. Outsourced Manufacturing

The decision to outsource or retain in-house manufacturing hinges on regulatory strategy, capacity planning, and intellectual property (IP) considerations. Many pharmaceutical companies partner with specialized CMOs to accelerate time-to-market while maintaining quality control.

Distribution and Logistics Suppliers

Once manufactured, KYXATA’s distribution depends on a robust logistics network:

Global Logistics Providers:
- DHL Supply Chain & FedEx: Provide temperature-controlled transportation, critical for biologics and temperature-sensitive drugs.
- UPS Healthcare: Offers tailored solutions for pharmaceutical delivery, ensuring compliance with Good Distribution Practice (GDP).
Cold Chain Management:

Maintaining the integrity of KYXATA from manufacturing site to end-user requires cold chain solutions. Logistics providers with validated cold chain capabilities and real-time tracking are preferred.

Regulatory Considerations & Impact on Suppliers

Regulatory agencies such as the FDA, EMA, and PMDA impose strict standards for API manufacturing, formulation, and distribution. Suppliers must demonstrate compliance through GMP certifications, regular audits, and regulatory filings, impacting supplier selection and sustainability.

Certification and Quality Audits: Suppliers are subject to ongoing inspection and certification renewal.
Supply Chain Transparency: Increasing regulatory demands emphasize traceability, compelling KYXATA’s supply chain to integrate digital solutions for supplier qualification and monitoring.

Emerging Trends and Supply Chain Risks

Supply Chain Resilience: The COVID-19 pandemic highlighted vulnerabilities, prompting KYXATA’s manufacturers to diversify suppliers and establish regional manufacturing hubs.
Sustainability and Ethical Sourcing: Stakeholders increasingly demand environmentally responsible sourcing, influencing supplier selection.
Technological Integration: Use of blockchain and IoT enhances traceability, quality assurance, and freshness management throughout the supply chain.

Conclusion

The supply chain of KYXATA reflects a sophisticated network involving global API manufacturers, excipient suppliers, contract manufacturing organizations, and logistics providers. Suppliers like Lonza, Fujifilm Diosynth, Catalent, and DHL dominate critical nodes, supported by regional suppliers to mitigate risks. Ensuring strict regulatory compliance, technological innovation, and supply chain resilience will be vital as KYXATA advances toward broader market penetration.

Key Takeaways

Effective sourcing of APIs from reputable suppliers such as Lonza and Fujifilm Diosynth ensures high-quality production for KYXATA.
Strategic partnerships with CMOs like Catalent and Samsung Biologics facilitate scalable manufacturing and fill-finish services.
Cold chain logistics providers like DHL and FedEx are essential for maintaining drug integrity during distribution.
Regulatory compliance and supply chain transparency are critical, influencing supplier qualification processes.
Diversification and technological integration mitigate risks and enhance supply chain resilience, particularly amidst global disruptions.

FAQs

1. Who are the primary API suppliers for KYXATA?
Leading API suppliers include Lonza Group, Fujifilm Diosynth Biotechnologies, and Boehringer Ingelheim, chosen for their GMP-certified facilities and expertise in biologics.

2. What role do contract manufacturing organizations play in KYXATA’s supply chain?
CMOs such as Catalent and Samsung Biologics handle formulation, manufacturing, and fill-finish processes, enabling scalable and compliant production.

3. How does KYXATA ensure cold chain integrity during distribution?
Through partnerships with logistics providers like DHL Supply Chain, employing temperature-controlled transportation and real-time tracking systems.

4. What regulatory factors influence KYXATA’s supply chain?
Regulatory agencies require GMP compliance, certification, and transparent supply chain practices, prompting suppliers to adhere to strict standards.

5. What are the current risks to KYXATA’s supply chain?
Disruptions include geopolitical tensions, global health crises, and manufacturing bottlenecks, mitigated by supplier diversification and technological enhancements.

Sources

Suppliers and packagers for kyxata

kyxata

Suppliers for the Pharmaceutical Drug: KYXATA